Companies / Shattuck Labs, Inc. / Activity
Activity — Shattuck Labs, Inc.
24 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 25, 2026 | Stout Stephen Executive | Other | Common Stock | $2.5K | -593 -0.72% | 81,529 0.08% of shares | low |
| Jan 25, 2026 | DeYoung Casi Executive | Other | Common Stock | $9.5K | -2K -3.02% | 73,480 0.07% of shares | low |
| Jan 25, 2026 | Neill Andrew R Executive | Other | Common Stock | $10.7K | -3K -1.12% | 228,224 0.23% of shares | low |
| Jan 25, 2026 | Pandite Arundathy N. Executive | Other | Common Stock | $13.3K | -3K -1.60% | 196,219 0.20% of shares | low |
| Jan 10, 2026 | Stout Stephen Executive | Other | Common Stock | $19.7K | -4K -4.81% | 82,122 0.08% of shares | low |
| Jan 10, 2026 | DeYoung Casi Executive | Other | Common Stock | $27.1K | -6K -7.00% | 75,766 0.08% of shares | low |
| Jan 10, 2026 | Neill Andrew R Executive | Other | Common Stock | $31.6K | -7K -2.80% | 230,813 0.23% of shares | low |
| Jan 10, 2026 | Pandite Arundathy N. Executive | Other | Common Stock | $32.5K | -7K -3.32% | 199,414 0.20% of shares | low |
| May 22, 2026 | Siegall Clay B Director | Grant | Common Stock | $138.9K | +128K +100.00% | 256,108 0.26% of shares | low |
| Jun 9, 2026 | Siegall Clay B Director | Buy | Common Stock | $250.0K | +63K +24.40% | 318,608 0.32% of shares | medium |
| May 29, 2026 | Siegall Clay B Director | Grant | Stock Option (Right to Buy) | — | +81K | 81,000 0.08% of shares | low |
| May 22, 2026 | Siegall Clay B Director | Exercise | Warrants (Right to Buy) | — | -128K -100.00% | 0 0.00% of shares | low |
| Jun 11, 2026 | Orbimed Advisors LLC Director | Buy | Pre-Funded Warrants (right to buy) | — | +208K +4.09% | 5,303,908 5.28% of shares | low |
| Jun 11, 2026 | Orbimed Advisors LLC Director | Buy | Pre-Funded Warrants (right to buy) | — | +1.0M +4.09% | 26,519,541 26.42% of shares | low |
| Jun 8, 2026 | Orbimed Advisors LLC Director | Other | Common Warrants (right to buy) | — | -3.1M -100.00% | 0 0.00% of shares | low |
| Jun 8, 2026 | Orbimed Advisors LLC Director | Other | Common Warrants (right to buy) | — | -15.4M -100.00% | 0 0.00% of shares | low |
| Jun 8, 2026 | Orbimed Advisors LLC Director | Other | Pre-Funded Warrants (right to buy) | — | +3.1M +151.97% | 5,095,575 5.08% of shares | low |
| Jun 8, 2026 | Orbimed Advisors LLC Director | Other | Pre-Funded Warrants (right to buy) | — | +15.4M +151.97% | 25,477,874 25.39% of shares | low |
| Jan 10, 2026 | Pandite Arundathy N. Executive | Grant | Common Stock | — | +488K | 487,800 0.49% of shares | low |
| Jan 10, 2026 | Neill Andrew R Executive | Grant | Stock Option (Right to Buy) | — | +550K | 549,800 0.55% of shares | low |
| Jan 10, 2026 | Stout Stephen Executive | Grant | Stock Option (Right to Buy) | — | +351K | 351,400 0.35% of shares | low |
| Jan 10, 2026 | DeYoung Casi Executive | Grant | Common Stock | — | +382K | 381,600 0.38% of shares | low |
| Jan 10, 2026 | Shukla Abhinav A. Executive | Grant | Common Stock | — | +316K | 315,500 0.31% of shares | low |
| Jan 10, 2026 | Schreiber Taylor CEO | Grant | Stock Option (Right to Buy) | — | +1.5M | 1,548,300 1.54% of shares | low |